ImmunityBio, Inc. (IBRX) Reports Strong Q2 Growth, Eyes Lung Cancer and NMIBC Expansion

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. ImmunityBio, Inc. is one of them.

ImmunityBio, Inc. (NASDAQ:IBRX) is advancing its position as a leader in immunotherapy, focusing on cancer and immune disorders through its flagship therapy ANKTIVA®, which combines IL-15 superagonist N-803 with Bacillus Calmette-Guérin (BCG) for patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to BCG. The company is also expanding ANKTIVA’s use across new indications while progressing trials in lung cancer and lymphopenia.

In 2025, IBRX reported strong commercial momentum. Second-quarter revenue reached $26.4 million, up 60% from Q1, bringing year-to-date sales to $43 million. Since J-code approval streamlined reimbursement, unit sales have surged 246%. A lot of urology practices have joined the company’s Expanded Access Program for recombinant BCG, a move aimed at alleviating supply shortages and improving patient access. Internationally, the UK’s regulatory agency approved ANKTIVA plus BCG for BCG-unresponsive NMIBC carcinoma in situ, further broadening its market reach.

On the regulatory front, ImmunityBio, Inc. (NASDAQ:IBRX) is working closely with the FDA after receiving a Refuse-to-File letter for its supplemental biologics license application (sBLA) seeking expansion to papillary-only NMIBC. Meanwhile, the corporation is pushing for guideline updates through the National Comprehensive Cancer Network (NCCN), which could strengthen ANKTIVA’s adoption in U.S. clinical practice.

IBRX is also making progress in oncology trials. It launched the ResQ201A randomized trial evaluating N-803 with tislelizumab in second-line non-small cell lung cancer patients and is preparing international submissions for broader trial participation. Additionally, the FDA has shown support for the firm’s lymphopenia program, with expanded access now available for patients with solid tumors who failed first-line therapies.

To support these initiatives, ImmunityBio, Inc. (NASDAQ:IBRX) recently raised $80 million in equity financing, ensuring resources for ongoing regulatory discussions, clinical trials, and commercial expansion.

While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.